1. Home
  2. RZLT vs CGC Comparison

RZLT vs CGC Comparison

Compare RZLT & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

SELL

Current Price

$4.00

Market Cap

352.1M

Sector

Health Care

ML Signal

SELL

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

SELL

Current Price

$0.53

Market Cap

299.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RZLT
CGC
Founded
2010
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.1M
299.0M
IPO Year
2011
2023

Fundamental Metrics

Financial Performance
Metric
RZLT
CGC
Price
$4.00
$0.53
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $10.40
N/A
AVG Volume (30 Days)
1.5M
★ 2.4M
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
23.47
★ 84.17
EPS
N/A
★ N/A
Revenue
N/A
★ $12,759,000.00
Revenue This Year
N/A
$18.91
Revenue Next Year
$2,517.77
$6.82
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.53
52 Week High
$11.17
$2.38

Technical Indicators

Market Signals
Indicator
RZLT
CGC
Relative Strength Index (RSI) 46.33 26.28
Support Level $3.58 N/A
Resistance Level $4.22 $0.76
Average True Range (ATR) 0.36 0.05
MACD -0.01 -0.01
Stochastic Oscillator 35.74 0.39

Price Performance

Historical Comparison
RZLT
CGC

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

Share on Social Networks: